In­tel­lia re­ports case of liv­er tox­i­c­i­ty in AT­TR gene edit­ing study

In­tel­lia Ther­a­peu­tics dis­closed that one pa­tient in a Phase 3 study of its gene edit­ing treat­ment for a pro­gres­sive heart dis­ease ex­pe­ri­enced a se­ri­ous case …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER